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LAY SUMMARY 
 
Vibration controlled transient elastography is a non-invasive method of detecting 
liver fat and fibrosis in patients with nonalcoholic fatty liver disease.  
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ABSTRACT 
 
Background & Aims: Vibration-controlled transient elastography (VCTE), which 
measures liver stiffness, has become an important tool for evaluating patients 
with nonalcoholic fatty liver disease (NAFLD). We aimed to determine the 
diagnostic accuracy of VCTE in detection of NAFLD in a multicenter cohort of 
patients. 
 
Methods: We performed a prospective study of 393 adults with NAFLD who 
underwent VCTE within 1 year of liver histology analysis (median time, 49 days; 
interquartile range, 25–78 days), from July 1, 2014 through July 31, 2017.  Liver 
stiffness measurement (LSM) cutoffs for pairwise fibrosis stage and controlled 
attenuation parameter (CAP) cutoffs for pairwise steatosis grade were 
determined using cross-validated area under the receiver operating 
characteristics curve (AUROC) analyses. Diagnostic statistics were computed at 
sensitivity fixed at 90% and specificity fixed at 90%. 
 
Results: LSM identified patients with advanced fibrosis with an AUROC of 0.83 
(95% CI, 0.79– 0.87) and patients with cirrhosis with an AUROC of 0.93 (95% CI, 
0.90–0.97). At fixed sensitivity, a cutoff LSM of 6.5 kPa excluded advanced 
fibrosis with a negative predictive value of 0.91; a cut-off LSM of 12.1 kPa 
excluded cirrhosis with a negative predictive value of 0.99. At fixed specificity, 
LSM identified patients with advanced fibrosis with a positive predictive 0.71 and 
patients with cirrhosis with a positive predictive value of 0.41. CAP analysis 
detected steatosis with an AUROC of 0.76 (95% CI, 0.64–0.87). In contrast, the 
VCTE was less accurate in distinguishing lower fibrosis stages, higher steatosis 
grades, or presence of NASH. 
 
Conclusion: In a prospective study of adults with NAFLD, we found VCTE to 
accurately distinguish advanced vs earlier stages of fibrosis, using liver histology 
as the reference standard.   
 
KEY WORDS: NAFLD, VCTE, Fibrosis, Steatosis 
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INTRODUCTION 
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver 
disease in the U.S1. NAFLD exists as two predominant histological subtypes: 
nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) 2. NAFL is 
associated with a relatively benign clinical course, while NASH is associated with 
increased risk of progressive fibrosis and cirrhosis3. In NAFLD, liver biopsy remains the 
gold standard for diagnosis, assessing activity and staging fibrosis. However, routine use 
of liver biopsy is limited by its invasive nature, risk of complications, cost, sampling error, 
and poor patient acceptance4,5. This underscores an urgent need for non-invasive and 
accurate methods for disease detection and staging. Although, there are currently no 
reliable non-invasive means of differentiating NAFL from NASH, non-invasive models 
that correlate with individual histological parameters have been developed6,7. Hepatic 
steatosis and fibrosis are two of the most studied histological parameters as they are 
essential in disease diagnosis and staging, respectively. While several non-invasive 
methods for assessing steatosis and fibrosis have been evaluated, these all have major 
limitations8.  
Vibration controlled transient elastography (VCTE) measures the speed of a 
mechanically generated shear wave across the liver to derive a liver stiffness 
measurement (LSM), a marker of hepatic fibrosis9. Measuring the attenuation of 
ultrasound signal through the liver is used to derive the Controlled Attenuation 
Parameter (CAP), which is measured simultaneously with LSM as a marker of hepatic 
steatosis10. The performance of VCT  using the standard M probe in NAFLD was limited 
by high failure rates in patients with higher body mass index (BMI) and skin to liver 
capsule distance11. To circumvent the high failure rate in obese patients, an XL probe 
was developed12. To further reduce the failure rate and standardize methodology, 
Fibroscan 502 Touch®, a probe selection software tool that automatically determines the 
choice of the probe based on skin to capsule distance, has been developed. With these 
improvements, the failure rate of VCTE was reported to be <5%13. Despite the growing 
literature with VCTE in NAFLD, there are only a few single center studies evaluating the 
accuracy of both M and XL probes in American cohorts14,15. The aim of the current study 
is to examine the diagnostic accuracy of VCTE in assessing steatosis and fibrosis in a 
multi-center cohort of American adults with biopsy proven NAFLD.   
 
 
METHODS 
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Study Design:  
All subjects included in this study were prospectively enrolled as part of the NIH 
funded NASH Clinical Research Network (NASH CRN) NAFLD Database 2 study with 
inclusion and exclusion criteria as previously reported13. Eligible adult subjects (age ≥ 18 
years) were enrolled across eight medical centers in the United States13. All subjects 
had biopsy-proven NAFLD within twelve months of the VCTE examination. Data were 
stored, monitored and analyzed at the Data Coordinating Center at the John Hopkins 
Bloomberg School of Public Health. The Institutional Review Boards at participating 
centers approved the study (NCT01030484) and all participants provided written 
informed consent prior to enrollment. All authors reviewed and approved the manuscript 
prior to submission. This study was conducted according to Transparent Reporting of a 
multivariate prediction model for Individual Prognosis or Diagnosis for biomarker 
development (see supplementary material) 16.  
 
Study Visit and Procedures: 
All subjects were evaluated at their respective medical center by a study 
investigator and research nurse after an overnight fast. Protocol driven anthropometric 
measurements, study-specific questionnaires, and blood tests were collected. All eligible 
subjects underwent VCTE examinations between July 1, 2014 and July 31, 2017.  
 
Liver Biopsy:  
All liver biopsies were scored for features of NAFLD using the NASH CRN 
scoring system by the Pathology Committee of the NASH CRN, who were blinded to the 
VCTE and clinical data2. Hepatic steatosis was graded ordinally from 0-3 [grade 0=<5% 
steatosis; grade 1=5-33% steatosis, grade 2=34-66% steatosis; grade 3=≥67% 
steatosis]. Hepatic fibrosis was quantified from stages 0-4 and for the purposes of this 
analysis advanced fibrosis was defined as fibrosis stage≥3 with cirrhosis as stage 4. The 
presence of definite NASH was defined according the NASH CRN criteria2. Portal 
inflammation, lobular inflammation and cytological ballooning was graded ordinally 
according the NASH CRN histological scoring system. 
 
Vibration Controlled Transient Elastography (VCTE):  
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VCTE was performed using Fibroscan® 502 Touch, which were provided by 
Echosens (Paris, France) to all the NASH-CRN sites through a Clinical Trial Agreement 
with the NIDDK.  
Trained study coordinators or principal investigators performed all VCTE 
examinations using a standardized protocol13. Subjects were placed in supine position 
with the right arm in maximal abduction and measurements were taken over the right 
hepatic lobe through an intercostal space13. All studies were started using the M probe 
with transition to the XL probe only if prompted by the device’s automatic probe selection 
tool. Only cases with ≥10 valid acquisitions were used. Either the same or a different 
certified technician repeated the VCTE exam at the same session. The mean of the two 
VCTE exams was used to obtain higher statistical power due to lower variability when 
using mean as opposed to a single measurement. To evaluate the impact of using the 
first reading compared to the mean of the two VCTE examination, summary statistics 
between the first and second examination were compared. Unreliability of LSM was 
defined as IQR/Median >30% and technical failure was defined by the inability to obtain 
10 valid measurements. The LSM and CAP measurements used for this analysis were 
the mean of the medians obtained with the 2 exams. If one exam was missing or had 
unreliable data, the data from the completed exam was used13. 
 
Statistical Analysis 
Summary statistics include means, standard deviations and percentages. 
Diagnostic statistics include sensitivity, specificity, positive predictive value, negative 
predictive value and cross-validated (using jack-knife procedure) using area under the 
ROC (AUROC) and 95% confidence intervals. Diagnostic statistics and liver stiffness 
measurement (LSM) cut-offs for increasing pairwise fibrosis stages (0 vs 1-4, 0-1 vs 2-4, 
0-2 vs 3-4 and 0-3 vs 4) and controlled attenuation parameter (CAP) cutoffs for 
increasing pairwise steatosis grades (0 vs 1-3, 0-1 vs 2-3 and 0-2 vs 3) were estimated 
at (1) optimized sensitivity and specificity (via Youden Index), (2) sensitivity fixed at 90% 
and (3) specificity fixed at 90%. Similarly, diagnostic statistics for detecting presence of 
NASH using LSM, CAP and the combination of CAP and LSM were determined. To 
evaluate the impact of the time interval between liver biopsy and VCTE, the cohort was 
sub-divided into those who had a liver biopsy and VCTE within versus greater than 30 
days.  The diagnostic accuracy of VCTE in those two cohorts was evaluated by 
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comparing AUROC. Finally sensitivity analysis was performed to assess the 
performance of VCTE between first and second measurements.  
To evaluate impact of the liver histology on LSM, multiple linear regression 
models were constructed with steatosis, lobular and portal inflammation, ballooning, 
fibrosis and body mass index as candidate covariates and LSM as the outcome variable. 
To evaluate the impact of the liver histology on CAP,  multiple linear regression models 
were constructed with steatosis, portal and lobular inflammation, ballooning, fibrosis and 
body mass index as candidate covariates and CAP as the outcome variable. Final model 
selection was based on Akaike’s Information Criteria. Analyses were conducted using 
SAS (Version 9.3 of the SAS System for Windows, Cary, NC: SAS Institute Inc., 2002-
2004) and Stata (StataCorp. 2015. Stata Statistical Software: Release 14. College 
Station, TX: StataCorp LP). 
 
RESULTS: 
Study Population 
A total of 393 subjects met inclusion criteria and were included in the analysis. 
Thirty-five subjects had missing CAP data while using the XL probe at the beginning of 
the study as software to compute CAP values was not available on XL probe. The 
median [quartiles] absolute value of time from liver biopsy to VCTE was 49 (25, 78) 
days. The mean (±SD) age and BMI of the cohort was 51±11 years and 34±6kg/m2, 
respectively (Table 1). The distribution of biopsy fibrosis stage 0, stage 1, stage 2, stage 
3, and stage 4 was 24%, 25%, 19%, 23%, and 9%, respectively.  The distribution of 
biopsy steatosis grade for grade 0, 1, 2, and 3 was 5%, 38%, 30% and 27%, 
respectively. Twenty-one (2.7%) of the 786 LSM measurements had unreliable results, 
and the failure rate was 3.7% (reasons for failure: 7 subjects had skin-to-capsule 
distance >3.5cm; 4 cases where the machine was not working or available and 4 cases 
where the patient stopped or refused).  
 
Performance Diagnostics of Liver Stiffness Measurements 
The median LSM scores for fibrosis stages 0, 1, 2, 3, and 4 were 5.5[4.5, 7.4], 
6.5[5.0, 8.8], 7.7[6.6, 10.6], 11.2[8.3, 13.8], and 23.2[14.8, 45.8] kPa, respectively 
(Figure 1). There were two participants with stage 0 fibrosis but outlier LSM values of 
69.2kPa and 45.1kPa. The first patient’s examinations had LSM values of 69.2kPa and 
45.0kPa on first and second exam with IQR/median of 15% and 44%, respectively by the 
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same performer.  According to the study design, the results of the second exam were 
excluded since IQR/median was >30%. On histology, this participant had NAFLD with 
NAS=1 and had BMI of 32.9kg/m2. The second patient’s examinations had LSM of 
19.6kPa (IQR/median=12%) and 70.6kPa (IQR/median=15%) using different examiners 
with the average value of 45.1kPa. On histology, the participant had NAFLD with NAS=2 
and had BMI of 45.0kg/m2.  
The cross-validated AUROC for classifying fibrosis stage 0 from stages 1-4 was: 
0.74 (95% CI 0.68, 0.79); fibrosis stages 0-1 from stages 2-4 was: 0.79 (0.74-0.83); 
fibrosis stages 0-2 from stages 3-4 was: 0.83 (0.79, 0.87); and fibrosis stages 0-3 was: 
0.93 (0.90, 0.97) (Table 2). The LSM cutoff values with sensitivity fixed at 90% for 
differentiating between dichotomous fibrosis stages are as follows: 4.9kPa for stages 0 
vs. stages 1-4; 5.6kPa for stage 0-1 vs. stages 2-4; 6.5kPa for stages 0-2 vs. stages 3-4; 
and 12.1kPa for stages 0-3 vs. stage 4. Using these LSM cutoff values, the PPV was 
0.80, 0.62, 0.45 and 0.34 and NPV was 0.48, 0.80, 0.91, and 0.99 for discriminating 
between stage 0 vs. stages 1-4, stage 0-1 vs. stages 2-4, stages 0-2 vs. stages 3-4, and 
stage 0-3 vs. stage 4, respectively (Table 2). In contrast, with specificity fixed at 90%, 
the LSM cutoff values for discriminating fibrosis stage 0 vs.  stages 1-4, stages 0-1 vs. 
stages 2-4, stages 0-2 vs. stages 3-4, and stages 0-3 vs. stage 4 were 9.4kPa, 11.9kPa, 
12.1kPa and 14.9kPa, respectively. The PPV was 0.93, 0.80, 0.71, and 0.41, 
respectively for differentiating between stage 0 vs. stages 1-4, stage 0-1 vs. stages 2-4, 
stages 0-2 vs. stages 3-4, and stage 0-3 vs. stage 4, while corresponding NPV were 
0.34, 0.59, 0.80, and 0.97 (Table 2).    Finally, the cutoff value optimizing sensitivity and 
specificity for differentiating stage 0 from stages 1-4 was 8.6kPa; stages 0-1 vs. stages 
2-4 was 8.6kPa; stages 0-2 vs. stages 3-4 was 8.6kPa; and stages 0-3 vs. stage 4 was 
13.1kPa (Table 2).  The diagnostic accuracy of LSM was not altered by the time interval 
between liver biopsy and VCTE (Table 3). Finally, sensitivity analysis showed no 
difference between LSM measurements from first and second exam (Supplemental 
Table 1 and 2).  
 
Performance Diagnostics of Controlled Attenuation Parameter 
The median CAP scores for steatosis grade 0, 1, 2 and 3 were 274[244, 281], 
306[270, 338], 340[312, 369], and 340[311, 360] dB/m (Figure 2). The cross-validated 
AUROC for classifying steatosis grade 0 vs. grade 1-2, steatosis grade 0-1 vs. 2-3, and 
steatosis grade 0-2 vs. 3 were 0.76 (95% CI: 0.64, 0.89), 0.70 (0.64, 0.75), and 0.58 
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(0.51, 0.64), respectively (Table 4). At sensitivity fixed at 90%, a cutoff value 263dB/m 
provided 0.35 specificity, 0.96 PPV, and 0.15 NPV for detecting presence of ≥5% 
steatosis. When the specificity was fixed at 90%, a cutoff value 353dB/m provided 
sensitivity of 0.29, PPV of 0.98 and NPV of 0.06. The cutoff values for differentiating 
between steatosis grade 0-1 vs. 2-3 and steatosis grade 0-2 vs. 3 at 90% fixed 
sensitivity were 280dB/m and 274dB/m and at 90% fixed specificity were 367dB/m and 
380dB/md specificity. The cutoff values optimizing sensitivity and specificity for 
differentiating steatosis grade 0 vs. grade 1-3 was 285dB/m; grade 0-1 vs. grade 2-3 
was 311dB/m; and grade 0-2 vs. grade 3 was 306dB/m (Table 3). Finally, the diagnostic 
accuracy of CAP was similar whether the time interval between liver biopsy and VCTE 
was less than 30 days or more than 30 days (Table 3). Using sensitivity analysis, there 
was no difference between CAP measurements obtained between first and second 
exam (Supplemental Table 1 and 2).  
 
Regression Models 
In regression analysis, fibrosis (β-coefficient 4.3kPa/stage [95% CI: 3.4, 5.2], 
P<0.001) and body mass index (β-coefficient 0.12kPa/kg/m2 [-0.03, 0.27], p=0.10) were 
directly related to LSM, while an inverse relationship between steatosis grade (β-
coefficient -1.8 kPa/grade [-2.9, -0.7], P=0.001) and ballooning (β-coefficient -
1.1kPa/grade [-2.5, 0.4], p=0.16) were found.  Portal and lobular inflammation were not 
related to LSM. A direct and significant relationship between CAP and steatosis (β-
coefficient of 17dB/m/grade [12, 22], P<0.001), portal inflammation (β-coefficient -
5.9dB/m/grade [-13.0, 1.2], P=0.10) and body mass index (β-coefficient 2.8dB/m/kg/m2 
[2.1, 3.5], p<0.001) were found (Supplemental Table 3).   
Although BMI was significantly related to both LSM and CAP, the diagnostic 
performance of LSM for assessing fibrosis and CAP for assessing steatosis did not vary 
by BMI category (Supplemental Table 4). The relationship between steatosis grade and 
LSM did not vary by presence or absence of advance fibrosis. Similarly, after adjusting 
for BMI, no significant relationship between LSM and CAP was noted (data not shown).  
 
Diagnostic Accuracy of VCTE in Predicting NASH 
 Among 358 subjects with definite NASH, the cross-validated AUROC for LSM 
was 0.74 (95% CI: 0.68, 0.79) with OR= 1.078 (1.034, 1.123) per kPa (P<0.001) for 
detecting the presence of NASH.  The cross-validated AUROC for CAP was 0.58 (0.52, 
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0.64) in detecting NASH with OR=1.007 (1.002, 1.011) per dB/m (P=0.003). Finally, the 
model with both LSM and CAP had an AUROC of 0.71 (0.66, 0.76) in diagnosing NASH 
with LSM OR=1.071 (1.028, 1.115) per kPa (P=0.001) and CAP OR=1.006 (1.001, 
1.011) per dB/m (P=0.02).  
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DISCUSSION: 
An important unmet need in NAFLD is a point of care test that can aid in 
detection and identification of advance fibrosis. VCTE can simultaneously detect 
steatosis and fibrosis, but there is paucity of data defining optimal use of VCTE in 
American cohorts14,15.  The current study evaluates the diagnostic accuracy of VCTE in a 
multicenter cohort with histologically confirmed NAFLD to assess parameters for clinical 
use by identifying threshold that are highly sensitive or specific.  
Early detection of NAFLD is vital to allow sufficient time to implement strategies 
aimed at favorably altering the natural history of the disease. The CAP value is positively 
associated with severity of hepatic steatosis and the cross-validated AUROC is 76% for 
classifying patients with  ≥5% steatosis on histology. This cutoff (CAP 263dB/m) is 
similar to the previously proposed cutoff in U.S. cohort17. In addition to clinical care, the 
CAP value may also be used as an adjunct tool in regulatory science to allow for subject 
enrichment in early phase clinical trials with non-histological endpoints. A CAP value < 
274 dB/m has 84% NPV for grades 0-2 steatosis (i.e., excludes grades 3 steatosis) 
suggesting that cut-off may offer some clinical and research utility.  In contrast, the 
accuracy of CAP in separating steatosis grade, particularly grade 2 and 3, was sub-
optimal, a finding that confirms prior reports10,14.  
In NAFLD, hepatic fibrosis is a key predictor of liver related outcomes3,18 and 
VCTE can be used to detect fibrosis, especially in its advance stage. Although VCTE is 
not a confirmatory test, it can help identify patients in whom additional histological 
assessment maybe warranted, while avoiding liver biopsies in patients with none to 
minimal fibrosis. Identifying optimal cutoff values of VCTE depends on the context of use 
for VCTE. Non-invasive biomarkers aim to either to minimize false negatives (i.e. high 
sensitivity) or to minimize false positives (i.e. high specificity) depending on whether 
VCTE is being used as screening modality or a tool to identify NAFLD patients with 
fibrosis with great degree of certainty. Moderate fibrosis is linked to liver related 
outcomes and mortality18, and a LSM <5.6kPa has a NPV of 80% for excluding 
moderate fibrosis. Similarly, a less invasive approach can be employed in patients with a 
LSM <6.5kPa since the presence of advance fibrosis can be excluded with at least 91% 
certainty. While higher LSM values allow for greater specificity and can be used to 
identify individuals in whom additional confirmatory histological assessment maybe 
warranted. Furthermore, we also applied cutoffs proposed by Baveno IV consensus for 
detection of advance fibrosis in our cohort and the published data15,19.  The cutoff values 
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of >9.9kPa had a PPV of 46% and 64% for detecting advance fibrosis in the cohorts 
studied by Tapper et. al. and the NASH CRN, respectively (Supplemental Table 3). The 
higher PPV observed in the NASH CRN cohort is likely due to higher prevalence of 
advance fibrosis within the NASH CRN cohort (32% vs. 18%).  Conversely, using a 
cutoff value >15kPa yielded a NPV of 75% with in the NASH CRN cohort. These findings 
is in line with the assertion that VCTE has good accuracy at extremes with low LSM 
essentially ruling out advanced disease and higher LSM values ruling in cirrhosis20. An 
interesting inverse relationship between LSM and steatosis grade and cytological 
ballooning was noted as has been reported previously21. This likely represents 
disappearance of classic histological components of NAFLD as patients progress to 
advance fibrosis22. Although inflammation has been shown to impact LSM in patients 
with chronic liver disease, no such association was noted in the current study23,24. This is 
likely due to the fact that inflammation in NAFLD is often less severe than is found in 
viral hepatitis.  Finally, the diagnostic accuracy of VCTE for distinguishing NAFL from 
NASH was also poor.   
There are several notable strengths of the current study. This multicenter study 
evaluated the accuracy of VCTE using both M and XL probes and Fibroscan® 502 
Touch software in a US cohort using a standardized and uniform protocol. Due to the 
multicenter design, the results are more generalizable than previously reported single 
center experiences14,15. The sample size of the current study is also larger than prior 
U.S. studies with more equal distribution of histological parameters, particularly steatosis 
and fibrosis. Finally, we found that a single patient scan for both LSM (S.D.=10.9 kPa) 
and CAP (S.D.-50 dB/m) are nearly as precise as the average of the two scans LSM 
(S.D.=11.0 kPa) and CAP (S.D.= 48 dB/m) with no bias between the first and second 
scans, thus a single scan can be used, unless there is some reason other than 
increased precision to do so.   
 
A potential limitation of the study is that VCTE and liver biopsy were not 
performed simultaneously. However, since fibrosis evolves slowly, it is unlikely that the 
relatively short delay between biopsy and VCTE had any significant impact on LSM. 
Although, the delay between liver biopsy and VCTE did not impact the diagnostic 
accuracy of LSM or CAP, the power to detect such interactions was low.  The current 
study evaluated patients enrolled in an observational research study, and the diagnostic 
performance of VCTE cannot be extrapolated primary care clinics where the prevalence 
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and the severity of disease may be different.  Thus, the PPV and NPV reported in the 
NASH CRN cohort maybe different than in primary care clinics.  
In summary, VCTE is a non-invasive point of care tool that can be used in clinical 
practice for identifying steatosis and advance fibrosis in patients with NAFLD. VCTE may 
be useful in identifying patients in whom additional histological assessment may be 
warranted due to the presence of advance fibrosis, while excluding patients without 
significant fibrosis in whom a liver biopsy may be unnecessary.  
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Table 1. Selected Characteristics of the Study Population  
 Mean ± SD or n (%) 
N 393 
Age –years 51±11 
Gender -  male 127 (32%) 
Race - white 314 (80%) 
Ethnicity -  Hispanic 49 (13%) 
LABORATORY 
 
AST (U/L) 49±37 
ALT (U/L) 64±44 
Alkaline phosphatase (U/L) 83±32 
GGT (U/L) 70±83 
Bilirubin, total (mg/dL) 0.7±0.6 
International normalized ratio 1.04±0.13 
Platelet count (1000 cells/uL) 235±72 
METABOLIC FACTORS 
 
Body mass index (kg/m2) 
Diabetes 
Severe obesity (BMI ≥35 kg/m2) 
Dyslipidemia 
34.4±6.4 
170 (44%) 
163 (42%) 
221 (57%) 
HISTOLOGY 
 
Ballooning mean grade 
   Grade 0 
   Grade 1 
   Grade 2 
0.9±0.8 
143 (36%) 
132 (34%) 
118 (30%) 
Lobular inflammation – mean 
grade    
   Grade 0 
   Grade 1 
   Grade 2 
   Grade 3 
 
1.6±0.7 
5 (1%) 
211 (54%) 
130 (33%) 
47 (12%) 
Steatosis – mean grade 
   Grade 0 
   Grade 1 
   Grade 2 
   Grade 3 
1.8±0.9 
19 (5%) 
150 (38%) 
119 (30%) 
105 (27%) 
 NAFLD Activity Score (NAS) 4.3±1.7 
Portal inflammation – mean 
grade 
   Grade 0 
   Grade 1 
   Grade 2 
 
1.2±0.6 
45 (11%) 
234 (60%) 
114 (29%) 
Fibrosis – mean stage  1.7±1.3 
Stage 0 94 (24%) 
Stage 1  99 (25%) 
Stage 2  73 (19%) 
Stage 3  91 (23%) 
Stage 4  36 (9%) 
Definite NASH 225 (57%) 
Time from biopsy to VCTE – 
absolute value (days) 
 
  Mean±SD 64±64 
  Median [IQR] 49 [25, 78] 
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Table 2. Performance diagnostics of liver stiffness measurement assessing liver fibrosis stage 
 
Fibrosis 
stage: 
Non-event vs 
event 
Prevalence of 
event 
Cross-
validated 
AUROC  
(95% CI) 
Cutoff 
Criteria 
Cutoff 
(kPa) 
 
Sensitivity Specificity 
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
0 vs 1-4 76% 0.74 
(0.68, 0.79) Sensitivity = 90% 4.9 0.90 0.31 0.80 0.48 
   Specificity = 90% 9.4 0.46 0.90 0.93 0.34 
   Youden’s index 8.6 0.53 0.87 0.93 0.37 
         
0-1 vs 2-4 51% 0.79 
(0.74, 0.83) Sensitivity = 90% 5.6 0.90 0.44 0.62 0.81 
   Specificity = 90% 11.9 0.40 0.90 0.80 0.59 
   Youden’s index 8.6 0.66 0.80 0.78 0.70 
         
0-2 vs 3-4 32% 0.83 
(0.79, 0.87) Sensitivity = 90% 6.5 0.90 0.47 0.45 0.91 
   Specificity = 90% 12.1 0.52 0.90 0.71 0.80 
   Youden’s index 8.6 0.80 0.74 0.59 0.89 
         
0-3 vs 4 9% 0.93 
(0.90, 0.97) Sensitivity = 90% 12.1 0.90 0.82 0.34 0.99 
   Specificity = 90% 14.9 0.69 0.90 0.41 0.97 
   Youden’s index 13.1 0.89 0.86 0.39 0.99 
Abbreviations: AUROC; area under the receiver operating characteristic 
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Table 3. AUROCs by length of time between VCTE exam and biopsy 
*not cross-validated 
 
 
Predictor Outcome AUROC* P-value 
from test of 
independence 
of AUROCs 
  VCTE exam and 
biopsy within 
30 days 
(n=119) 
VCTE exam and 
biopsy outside 
of 30 days 
(n=274) 
LSM Fibrosis stage 
0 vs 1-4 
0.76 0.75 0.85 
 Fibrosis stage 
 0-1 vs 2-4 
0.76 0.80 0.44 
 Fibrosis stage 
 0-2 vs 3-4 
0.87 0.82 0.27 
 Fibrosis stage 
 0-3 vs 4 
0.95 0.93 0.56 
 
CAP Steatosis grade 
 0 vs 1-3 
0.86 0.75 0.33 
 Steatosis grade 
 0-1 vs 2-3 
0.77 0.67 0.09 
 Steatosis grade 
0-2 vs 3 
0.63 0.58 0.41 
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Table 4: Performance diagnostics of controlled attenuation parameter in assessing 
steatosis grade 
 
Steatos
is 
grade: 
Non-
event 
vs 
event 
Preval
ence 
of 
event 
Cross-
validated 
AUROC  
(95% CI) 
Cutoff 
Criteria 
Cutoff 
(dB/m) 
 
Sensiti
vity 
Specif
icity 
Positi
ve 
Predic
tive 
Value 
Negati
ve 
Predict
ive 
Value 
0 vs 1-3 95% 0.76  
(0.64, 
0.89) 
Sensitivity 
= 90% 263 0.90 0.35 0.96 0.15 
   Specificity 
= 90% 353 0.29 0.90 0.98 0.06 
   Youden’s 
index 285 0.80 0.77 0.99 0.16 
         
0-1 vs 
2-3 
58% 0.70  
(0.64, 
0.75) 
Sensitivity 
= 90% 280 0.90 0.35 0.64 0.72 
   Specificity 
= 90% 367 0.20 0.90 0.70 0.46 
   Youden’s 
index 311 0.77 0.57 0.70 0.66 
         
0-2 vs 3 27% 0.58  
(0.51, 
0.64) 
Sensitivity 
= 90% 274 0.90 0.20 0.29 0.84 
   Specificity 
= 90% 380 0.03 0.90 0.10 0.72 
   Youden’s 
index 306 0.80 0.40 0.32 0.85 
Abbreviations: AUROC; area under the receiver operating characteristic, 
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FIGURE LEGEND:  
 
Figure 1. Liver Stiffness Measurement According to Fibrosis Stage 
 
Figure 2. Controlled Attenuation Parameter According to Steatosis Grade 
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Appendix Table 1. Comparison of summary statistics between first vs. second VCTE exam 
 First exam Second exam Mean (First,  
Second) exam 
Difference (First – 
Second) exam 
LSM – kPa     
 N 385 375 393 367 
 Mean 10.9 11.0 11.0 -0.2* 
 SD 10.9 11.4 11.0 4.4 
     
CAP – dB/m     
 N 358 352 358 352 
 Mean 319 320 319 0† 
 SD 50 52 48 36 
*P-value from t-test of Difference=0 is 0.32 
†P-value from t-test of Difference=0 is 0.97 
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Appendix Table 2. Comparison of diagnostic performance between first vs. second VCTE exam 
Predictor Outcome AUROC P-value 
   First exam Second exam 
LSM Fibrosis stage 
0 vs 1-4 
0.74 0.76 0.72 
 Fibrosis stage 
 0-1 vs 2-4 
0.80 0.79 0.78 
 Fibrosis stage 
 0-2 vs 3-4 
0.84 0.83 0.70 
 Fibrosis stage 
 0-3 vs 4 
0.93 0.94 0.53 
     
CAP Steatosis grade 
 0 vs 1-3 
0.78 0.76 0.86 
 Steatosis grade 
 0-1 vs 2-3 
0.70 0.68 0.64 
 Steatosis grade 
0-2 vs 3 
0.61 0.56 0.25 
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Appendix Table 3. Linear regressions of Liver Stiffness Measurement (LSM) on NAFLD Activity Score 
(NAS) stratified by fibrosis stage 
  kPa / NAS  
Fibrosis stage N Slope 95% CI P-value 
0 94 -1.7 -3.1, -0.3 0.02 
1 99 0.6 0.1, 1.0 0.01 
2 73 0.2 -0.4, 0.8 0.56 
3 91 1.2 0.3, 2.2 0.01 
4 36 -4.1 -7.8, -0.3 0.03 
Note: P-value for test of interaction of fibrosis stage by NAS on LSM < 0.001 
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Appendix Table 4. Area under the receiver operating characteristic (AUROC) for liver stiffness 
measurement assessing fibrosis stage and controlled attenuation parameter assessing steatosis grade 
by body mass index* (BMI) 
  AUROC  
Outcome Non-event vs 
event  
comparison 
BMI < 30 
kg/m
2
 
BMI ≥ 30 & 
< 35 kg/m
2
 
BMI ≥ 35 
kg/m
2
 
P-value† 
Fibrosis stage  N=107 N=118 N=163  
 0 vs 1-4 0.75 0.81 0.68 0.22 
 0-1 vs 2-4 0.80 0.84 0.72 0.08 
 0-2 vs 3-4 0.89 0.85 0.77 0.06 
 0-3 vs 4 0.96 0.91 0.94 0.50 
      
Steatosis grade  N=104 N=104 N=145  
 0 vs 1-3 0.79 0.90 0.68 0.20 
 0-1 vs 2-3 0.80 0.64 0.71 0.07 
 0-2 vs 3 0.68 0.55 0.61 0.29 
*5 participants had missing bmi data 
†Based on test of equality of AUROCs across 3 bmi categories (ROC analysis of independent samples; 
Stata 15.1, 2017) 
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TRIPOD Checklist: Prediction Model Validation 
Section/Topic Item Checklist Item Page 
Title and abstract 
Title 1 Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted. 1 
Abstract 2 Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions. 3 
Introduction 
Background 
and objectives 
3a 
Explain the medical context (including whether diagnostic or prognostic) and rationale 
for developing or validating the multivariable prediction model, including references to 
existing models. 
4-5 
3b Specify the objectives, including whether the study describes the development or 
validation of the model or both. 5 
Methods 
Source of data 
4a Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable. 5-7 
4b Specify the key study dates, including start of accrual; end of accrual; and, if 
applicable, end of follow-up.  6 
Participants 
5a Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres. 6 
5b Describe eligibility criteria for participants.  5-6 
5c Give details of treatments received, if relevant.  n/a 
Outcome 6a 
Clearly define the outcome that is predicted by the prediction model, including how 
and when assessed.  7 
6b Report any actions to blind assessment of the outcome to be predicted.  6 
Predictors 
7a Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured. 7-8 
7b Report any actions to blind assessment of predictors for the outcome and other predictors.  n/a 
Sample size 8 Explain how the study size was arrived at. n/a 
Missing data 9 Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.  5-7 
Statistical 
analysis 
methods 
10c For validation, describe how the predictions were calculated.  7 
10d Specify all measures used to assess model performance and, if relevant, to compare 
multiple models.  7 
10e Describe any model updating (e.g., recalibration) arising from the validation, if done. n/a 
Risk groups 11 Provide details on how risk groups were created, if done.  n/a 
Development 
vs. validation 12 
For validation, identify any differences from the development data in setting, eligibility 
criteria, outcome, and predictors.  n/a 
Results 
Participants 
13a 
Describe the flow of participants through the study, including the number of 
participants with and without the outcome and, if applicable, a summary of the follow-
up time. A diagram may be helpful.  
7-8 
13b 
Describe the characteristics of the participants (basic demographics, clinical features, 
available predictors), including the number of participants with missing data for 
predictors and outcome.  
6-7 
13c For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).  7-8 
Model 
performance 16 Report performance measures (with CIs) for the prediction model. 8-11 
Model-updating 17 If done, report the results from any model updating (i.e., model specification, model performance). n/a 
Discussion 
Limitations 18 Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).  13 
Interpretation 
19a For validation, discuss the results with reference to performance in the development data, and any other validation data.  
11-
12 
19b Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.  11-13 
Implications 20 Discuss the potential clinical use of the model and implications for future research.  13 
Other information 
Supplementary 
information 21 
Provide information about the availability of supplementary resources, such as study 
protocol, Web calculator, and data sets.  n/a 
Funding 22 Give the source of funding and the role of the funders for the present study.  2 
 
We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document. 
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EDITOR’S NOTE: 
 
BACKGROUND AND CONTEXT 
 
Nonalcoholic fatty liver disease (NAFLD) is common in the United States and hepatic 
fibrosis is a key predictor of liver related outcomes in NAFLD. Vibration controlled 
transient elastography (VCTE) is a non-invasive biomarker that utilizes shear wave 
elastography to estimate hepatic fibrosis.  
 
NEW FINDINGS 
VCTE has high diagnostic accuracy for identifying presence of advance fibrosis and 
cirrhosis in patients with NAFLD.  
 
LIMITATIONS 
The study did not evaluate the impact of VCTE on clinical outcomes. 
 
IMPACT 
VCTE can be used as a clinical tool in management of patients with NAFLD.  
